The global sales of automated nucleic acid extraction systems are estimated to be worth USD 4,643.3 million in 2024 and anticipated to reach a value of USD 10,117.7 million by 2034.Sales are projected to rise at a CAGR of 8.1% over the forecast period between 2024 and 2034. The revenue generated by automated nucleic acid extraction systems in 2023 was USD 4,295.4 million.
Early detection of diseases, including genetic disorders, cancer, and infectious diseases is becoming essential to improves the patient outcome and also the overall burden of health care. Given the increasing prevalence of genetic conditions around the world, there is greater need for rapid and efficient diagnostic tools that are accurate in disease diagnosis.
Automated nucleic acid extraction systems are crucial for making such early diagnosis possible, as they ensure that DNA and RNA of high quality can always be efficiently isolated within a short time frame from various biological samples.
Global Automated Nucleic Acid Extraction Systems Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2023 | USD 4,295.4 million |
| Estimated Size, 2024 | USD 4,643.3 million |
| Projected Size, 2034 | USD 10,117.7 million |
| Value-based CAGR (2024 to 2034) | 8.1% |
Increasing molecular diagnostic technologies are now diagnosing genetic disorders, such as cystic fibrosis, Huntington's disease, and sickle cell anemia, at early stages. Such early diagnosis often enables timely intervention through gene therapy, prescribed medicine tailored to the patient, and lifestyle changes that can impact the quality of life for the patient. The genetic testing technique involves the precise removal of nucleic acids (DNA or RNA) in automated nucleic acid extraction systems, thus also minimizing contamination and degradation.
The automated nucleic acid extraction systems are indispensable for the identification of genetic markers, mutations, or specific RNA profiles associated with many cancers, including breast, lung, and colorectal. Technologies such as liquid biopsy have relied on accurate efficient nucleic acid extraction for mutation identification related to either cancer or tumor DNA circulating in the patient blood.
This automated nucleic acid extraction system has a highly significant role in the diagnosis of diseases, particularly in diseases such as COVID-19, tuberculosis, and influenza, which would stop disease transference if they were detected accurately.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The below table presents the expected CAGR for the global automated nucleic acid extraction systems market over several semi-annual periods spanning from 2024 to 2034. In the first half (H1) of the decade from 2023 to 2033, the business is predicted to surge at a CAGR of 9.3%, followed by a slightly lower growth rate of 8.7% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 9.3% (2023 to 2033) |
| H2 | 8.7% (2023 to 2033) |
| H1 | 8.1% (2024 to 2034) |
| H2 | 7.7% (2024 to 2034) |
The above table presents the expected CAGR for the global automated nucleic acid extraction systems market over several semi-annual periods spanning from 2024 to 2034. In the first half (H1) of the decade from 2023 to 2033, the business is predicted to surge at a CAGR of 9.3%, followed by a slightly decline in growth rate of 8.7% in the second half (H2) of the same decade.
Moving into the subsequent period, from H1 2024 to H2 2034, the CAGR is projected to decrease slightly to 8.1% in the first half and increase moderately at 7.7% in the second half. In the first half (H1) the market witnessed an increase of 120.00 BPS while in the second half (H2), the market witnessed a decrease of 100.00 BPS.
Advancements in biomarker discovery is propelling the market growth for Automated Nucleic Acid Extraction Systems
Biomarker discovery development acts as the main force for growth in the automated nucleic acid extraction systems market and offers huge opportunities regarding diagnostics, therapeutics, and personalized medicine. Biomarkers, which are biological molecules indicative of a disease or condition, help understand disease mechanisms; enable early diagnosis; and inform treatment decisions.
Meanwhile, biomarker discovery efforts in cancer, infectious diseases, neurodegenerative disorders, and autoimmune diseases are increasingly focusing on the needs for advanced molecular technologies, mainly with high-throughput and exacting nucleic acid extraction at the backbone of biomarker research.
The most critical applications of biomarkers in oncology pertain to the detection of genetic mutations, tumor markers, and RNA signatures that indicate the presence of cancer or predict its progress. Fast-paced biomarker discoveries have reformed cancer diagnosis and treatment. Targeted therapies enable the identification of genetic mutations that now include BRCA1 and BRCA2 in breast cancer, among other oncogenes that influence the treatment modalities.
These systems are responsible for the successful processing and presenting of consistent, high-quality DNA and RNA samples that can go into further analysis with techniques such as PCR and NGS among other molecular diagnostic techniques. These systems are very important in the processing of large volumes of samples resulting from clinical research and diagnostic labs where precision and reproducibility are paramount.
The Rising Investment in Nanotechnology Research Is Creating a Strong Growth Trajectory for The Automated Nucleic Acid Extraction Systems Market
One of the major factors contributing to the significant growth of the automated nucleic acid extraction systems market is investment in research associated with nanotechnology. Nanotechnology has transformed many scientific disciplines, from molecular biology and diagnostics, by offering newer, more precise, effective, and innovative ways of manipulating and detecting nucleic acids.
The fast-developing field of nanotechnology, therefore, continuously demands high-quality nucleic acid extraction systems combined with automation to serve as the backbone for reliable sample preparation, which is an important aspect of nanotechnology-based assays and diagnostics.
Nanotechnology-enabled diagnostics, like nanopore sequencing, biosensors, and nanofluidic devices, are making great impacts on how nucleic acids will be detected and analyzed. Most of these technologies require highly specific and standardized nucleic acid extraction to ensure the accuracy and reliability of the subsequent detection processes.
The result had been a staggering growth curve that the Automated Nucleic Acid Extraction Systems Market had experienced due to increasing investments in nanotechnology research. As nanotechnology continues to innovate and effect changes in molecular diagnostics and personalized medicine, so does the requirement for automated systems that provide efficient, high-quality nucleic acid extraction. This interrelationship between both areas is driving both fields forward and has caused the change in health care and diagnostics.
The Trend Towards Laboratory Automation Is a Significant Driver for The Growth of the Automated Nucleic Acid Extraction Systems Market.
The technologies include various aspects entailed in the easy facilitation of laboratory processes that were conventionally performed manually. The automated nucleic acid extraction systems mark the transformation beginning in laboratories towards handling a large volume of samples with least human interference. The systems therefore save a lot of time in laboratory workflows by automating the tasks that are repetitive in sample preparation and nucleic acid isolation.
This efficiency is highly critical in high-throughput environments because the processing of many samples in minimal times would lead to quicker research outcomes and diagnostics for patients and ultimately increasing the product adoption rate.
Automation has its benefits regarding the reduction of human error, possibly greatly affecting the results of tests conducted. Inconsistencies are furthered during manual extraction due to differences in techniques, environmental conditions, and human fatigue.
This trend toward automation of laboratories acts as a strong driver for the automated nucleic acid extraction systems market. Because of workflow efficiency and reduction in human error, along with the advanced technologies these systems possess, their application in several areas, and economic benefits, these systems have become a significant part of modern laboratories. Thus, while the demand for fast, accurate, and reliable molecular diagnosis continues to increase, the role of automation in nucleic acid extraction will grow significantly.
The Limited Product Adoption Acts as a Barrier to the Automated Nucleic Acid Extraction Systems
The challenge in the implementation of automated nucleic acid extraction systems is that some nucleic acid tests are insensitive and not accurate, sometimes resulting in the misdiagnosis of several infectious diseases. Although these systems have been formulated to make DNA and RNA extraction from biological samples quick and very efficient, the efficiency however depends on a number of factors.
Whereas there is a constant interest in the development of automated nucleic acid extraction systems, which are capable of standardization and optimization of this process, performance may vary depending upon the kind of sample, quality, and system configuration. Poor isolation of nucleic acids owing to malfunctioning of these systems may lead to diagnostic tests that give false results.
Inaccurate isolation might also have its contribution to contamination and will give a false positive about disease conditions that are not present. Misdiagnosis based on inaccurate extractions could lead to serious clinical consequences, such as delayed or wrong treatments.
Although advanced, even automated systems of nucleic acid extraction face challenges in their working principles when they are dealing with highly diluted or degraded samples. If, in such cases, the system is unable to draw out enough nucleic acids from these low-concentration samples, diagnostic tests might miss critical markers for disease.
Principal Consultant
The global automated nucleic acid extraction systems industry recorded a CAGR of 7.3% during the historical period between 2019 and 2023. The growth of automated nucleic acid extraction systems industry was positive as it reached a value of USD 4,295.4 million in 2023 from USD 2,940.3 million in 2019.
The automated nucleic acid extraction systems market has had undergone major changes. For a long period of time, nucleic acid extraction was performed in the laboratory by manual handling; which was a labor-intensive process that generally poised a high risk of contamination and variability. Increasing demands within clinical diagnostics, molecular biology, and genomics for quicker, more reliable means accelerated developments of automated systems.
The manufacturing companies started producing more advanced automated systems. Robotics and microfluidics enabled systems for high-throughput capability with improvements in sample preparation and accuracy.
The future scenario for the automated nucleic acid extraction systems market is opportunistic with a range of latest technologies will get introduced into the market. Microfluidics-an advanced technology-is one of the latest areas of interest since this platform enables lower sample volume processing with higher precision at less reagent consumption. Lab-on-a-chip technologies have also been an emerging trend since these can handle nucleic acid extraction, amplification, and analysis on one single integrated device to be performed, saving time and labor.
Tier 1 companies comprise market leaders with a market revenue of above USD 100 million capturing significant market share of 51.5% in global market. These companies are industry leaders with advanced technological capabilities, extensive research and development efforts, and strong financial resources. Robust distribution networks and strategic partnerships with healthcare providers and technology firms go on to strengthen this leading market position. Prominent companies in tier 1 include Qiagen N.V, Roche Molecular Systems, Analytik Jena AG and Thermo fisher Scientific, Inc.
Tier 2 companies include mid-size players with revenue of USD 50 to 100 million having presence in specific regions and highly influencing the local market and holds around 28.5% market share. The automated nucleic acid extraction systems market is contributed to by tier 2 companies that have growing influence in the market.
Most of the companies are focused on specific niche areas within the area of nucleic acid extraction system. They invest in developing advanced devices and enhancing patient experience with the prime target of capturing segments of the market. Prominent companies in tier 2 include Accubiomed Co., Ltd., Autogen Inc. and DiagCor Bioscience Inc Lt,
Finally, Tier 3 companies, such as Taigen Bioscience Corporation and Bioneer Corporation. They specialize in specific products and cater to niche markets, adding diversity to the industry.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The section below covers the industry analysis for the automated nucleic acid extraction systems market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Asia Pacific, Europe, and others, is provided. The United States is anticipated to remain at the forefront in North America, with higher market share through 2034. In Asia Pacific, India is projected to witness a CAGR of 7.1% by 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| China | 6.7% |
| India | 7.1% |
| United States | 1.7% |
| South Korea | 5.4% |
| Canada | 3.0% |
| Spain | 3.6% |
| Germany | 1.8% |
| France | 2.6% |
India’s automated nucleic acid extraction systems market is poised to exhibit a CAGR of 7.1% between 2024 and 2034. Currently, it holds the highest share in the Asia Pacific market, and the trend is expected to continue during the forecast period.
India has experienced an outstanding increase of diagnostic centers with the demand of health services and change of technology in the medical field. More people adapt preventive health measures and undergo early diagnosis increasing demand for services and routine health checkups of medical practitioners facilitating growth in diagnostic services and equipment.
These diagnostic centers contribute toward increasing access to healthcare in general and, within the medical scope, enhance the scalability of molecular diagnostics across the country; hence, automated nucleic acid extraction systems place themselves as a much-needed tool in this growing market.
In conclusion, the scaling up of diagnostic centers scales up access to healthcare and molecular diagnostics over the Indian subcontinent, hence making the automated nucleic acid extraction system a very vital tool in such a burgeoning market.
United States automated nucleic acid extraction systems market is poised to exhibit a CAGR of 1.7% between 2024 and 2034. Currently, it holds the highest share in the North America market, and the trend is expected to continue during the forecast period.
The United States market is driven by the advanced technology coupled with high consumer demand. One of the major reasons for this dominance is the leading role that the country plays in applying innovative technologies to medical science. Companies based in the United States represent some of the innovators when it comes to designing and developing highly sophisticated kinds of automated nucleic acid extraction systems, characterized by accurate regulations and integrated with cutting-edge features like automatic settings, real-time monitoring, and increased comfort for patients.
Apart from technological advancement, high demand from consumers in the United States is also a driver for market growth. The United States health system focuses on quality care and advanced solutions, which influences hospitals and healthcare facilities to search for the latest technologies in automated nucleic acid extraction systems.
Germany automated nucleic acid extraction systems market is poised to exhibit a CAGR of 1.8% between 2024 and 2034. Currently, it holds the highest share in the Western Europe market, and the trend is expected to continue during the forecast period.
Germany also represents the highest adoption of automation, thus driving a major factor for growth in the automated nucleic acid extraction systems market. Germany has shown a culture for implementing advanced automation technologies in several industries for a long period, including healthcare and life sciences. This step toward automation has brought about a sea change with great enhancement in speed, accuracy, and efficiency in diagnostic laboratories.
These systems allow for efficient processing of large volumes of biological samples, reducing the time and labor associated with manual extraction methods. The need for precision, rapid turnover, and reproducibility of diagnostic tests has pushed German laboratories to adopt automated systems that would meet the increasing workload spurred by advancements in molecular diagnostics.
The section contains information about the leading segments in the industry. By type, the kits and consumables segment holds the highest market share of 59.3% in 2024.
| By Type | Kits and Consumables |
|---|---|
| Value Share (2024) | 59.3% |
These kits and consumables are comprised of reagents, buffers, and other necessary materials that are needed in nucleic acid extraction. These are also needed for the operability of automated systems. These are very standard due to the high use rate, as laboratories and diagnostic centers conduct frequent analyses that require their usage. While instruments for nucleic acid extraction systems are generally one-time investments, consumables need regular re-supply and hence the demand is contineous.
Additionally, the growing application of molecular diagnostics in diseased diagnosis, genetic testing, and research has been a key driver, further increasing demand for quality kits and consumables. Kits and consumables assure reliable and accurate results, which are a vital ingredient in sensitive procedures like PCR, next-generation sequencing, and other molecular assays.
Moreover, with increasing automation within laboratories, the deployment of standardized kits and consumables increases as it enhances accuracy and improves efficiency. This factor too acted as a catalyst in driving market growth in the segment.
| By End User | Pharmaceutical & Biotechnology Companies |
|---|---|
| Value Share (2024) | 28.6% |
Due to the high demand in drug development, research, and improved diagnostics, pharmaceuticals and biotechnology companies will be the major end users of the Automated Nucleic Acid Extraction Systems. This includes high-precision, high-throughput nucleic acid-DNA and RNA-extraction for applications such as new therapy development, personalized medicine, and vaccine development.
Such automated nucleic acid extraction systems support pharmaceutical and biotech companies in processing large sample volumes in a rapid and accurate way, enabling the identification of genetic markers and the understanding of the mechanism behind a disease. This accelerates the development of targeted treatments and therapies in focused areas like cancer research and gene therapy.
In summary the ongoing advancements in genetic research and drug development, pharmaceutical and biotechnology companies are expected to continue leading the demand for automated nucleic acid extraction systems and thereby driving the market growth.
The market players are imperatively employing strategic ways to compete and capture business shares, increasing product differentiation through new product launches and strategic acquisitions, and looking for strategic partners who can support them in widening their product portfolios for global market reach.
Recent Industry Developments in Automated Nucleic Acid Extraction Systems Market:
In terms of type, the industry is divided into instruments, kits and consumables.
In the terms of end user, the market is segmented into hospitals, diagnostic centres, forensic laboratories, pharmaceutical & biotechnology companies and academic research institutes.
Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia & Pacific, East Asia and Middle East and Africa (MEA) have been covered in the report.
The global automated nucleic acid extraction systems market is projected to witness CAGR of 8.1% between 2024 and 2034.
The global automated nucleic acid extraction systems industry stood at USD 4,295.4 million in 2023.
The global automated nucleic acid extraction systems market is anticipated to reach USD 10,117.7 million by 2034 end.
India is set to record the highest CAGR of 7.1% in the assessment period.
The key players operating in the global automated nucleic acid extraction systems market include Qiagen N.V.; Roche Molecular Systems, Inc.; Analytik Jena AG; Thermofisher Scientific; Accubiomed Co., Ltd.; Autogen Inc.; DiagCor Bioscience Inc Lt; Taigen Bioscience Corporation; Bioneer Corporation.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors 3.1. Macro-economic Factors 3.2. Market Dynamics 3.3. Recent Industry Developments 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034 4.1. Historical Analysis 4.2. Future Projections 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034 5.1. By Type 5.2. By End Use 5.3. By Region 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Type 6.1. Instruments 6.2. Kits and Consumables 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by End Use 7.1. Hospitals 7.2. Diagnostic Centres 7.3. Forensic Laboratories 7.4. Pharmaceutical & Biotechnology Companies 7.5. Academic Research Institutes 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region 8.1. North America 8.2. Latin America 8.3. East Asia 8.4. South Asia and Pacific 8.5. Western Europe 8.6. Eastern Europe 8.7. Middle East and Africa 9. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 10. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 11. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 12. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 13. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 15. Middle East and Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 16. Sales Forecast 2024 to 2034 by Type and End Use for 30 Countries 17. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 18. Company Profile 18.1. Thermo Fisher Scientific 18.2. Autogen, Inc. 18.3. QIAGEN 18.4. ELITechGroup 18.5. Analytik Jena AG 18.6. bioMérieux SA 18.7. Aurora Biomed Inc. 18.8. Biosynex Group 18.9. GENOLUTION 18.10. BioChain Institute Inc. 18.11. Promega Corporation 18.12. Roche Diagnostics 18.13. Bioneer Corporation 18.14. Taigen Bioscience Corporation
Explore Healthcare Insights
View Reports
Automated Nucleic Acid Extraction Systems Market
